Predictive and pharmacodynamic biomarkers of kinase inhibitors in renal cell carcinoma circulating tumor cells using the versa platform.
Joshua M. Lang(University of Wisconsin–Madison), David J. Beebe(University of Wisconsin–Madison), Stephanie M. Thiede(University of Wisconsin Carbone Cancer Center), E. Jason Abel(University of Wisconsin–Madison), Toni K. Choueiri(Harvard University), Jamie M. Sperger(University of Wisconsin–Madison), Rana R. McKay(University of California San Diego), Lindsay N. Strotman(University of Wisconsin–Madison), Scott M. Berry(John Innes Centre), Benjamin P. Casavant(University of Wisconsin–Madison), Jacob T Tokar(University of Wisconsin–Madison)
Cited by 0
Related Papers
The Immune Landscape of Cancer
|Immunity|2018|6.3k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2019|1.6k